Role of PCA3 test in clinical decision making for prostate cancer diagnosis
نویسندگان
چکیده
منابع مشابه
is there a role for genetic information in risk assessment and decision making in prostate cancer?
results a total number of 43 specimens were studied, from which 9 were obtained from patients with metastatic prostate cancer. the expression of five examined genes had no correlation with psa level and gleason score. the expression of amacr decreased in metastatic prostate cancer (p = 0.02). the expression of other genes showed no difference between metastatic and non-metastatic tumors (p > 0....
متن کاملPCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
The search for the biomarkers to precisely and non-invasively characterize the biology of prostate cancer (PCa) is the focus of many laboratories across the world. Although prostate-specific antigen (PSA) remains the standard diagnostic tool for PCa, its low specificity leads to unnecessary biopsies in a substantial number of patients. More importantly, with the current status of knowledge, it ...
متن کاملThe Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer
Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. Although increased expression of prostate-specific antigen (PSA) is an effective indicator for the recurrence of PCa, its intended use as a screening marker for PCa is of considerable controversy. Recent research efforts in the field of PCa biomarkers have focused on the identification of tissue and fluid-based...
متن کاملthe accuracy of transrectal ultrasound-guided biopsy for decision making in prostate cancer
background the most important surgical complications of renal transplantation are stenosis and obstruction of anastomosis of the ureter to the bladder. hence, routine use of ureteral stents to prevent such complications seems logical; however, the optimal time to remove the ureteral stent is still controversial. objectives the purpose of this study was to compare the benefits and complications ...
متن کاملDecision-making in Prostate Cancer Treatment
Today, most men who have localized prostate cancer at diagnosis and who undergo either active surveillance or curative treatment can expect to have a disease-specific survival of at least 10 years2–4. Even men with metastatic disease can expect increased survival as new therapeutic agents become available and alternative regimes for existing treatments are tried5,6. Those facts, combined with a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Clinical Urology
سال: 2015
ISSN: 2219-2816
DOI: 10.5410/wjcu.v4.i1.68